CoChat

B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides

Jahrsdorfer, Bernd, Mühlenhoff, Lars, Blackwell, Sue E., Wagner, Moritz, Poeck, Hendrik, Hartmann, Evelyn, Jox, Ralf, Giese, Thomas, Emmerich, Bertold, Endres, Stefan, Weiner, George J., Hartmann, Gunther · 2005 · Clinical Cancer Research
Cited by 121

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Human B cells detect CpG motifs within microbial DNA via TLR9. Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B cell non-Hodgkin's lymphoma. However, there is only limited information on the CpG oligodeoxynucleotide sensitivity of primary malignant B cells of different non-Hodgkin's lymphoma entities. Here we found that most B-cell malignancies except plasmacytoma respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation. In an in vitro analysis of 41 individual patient-derived primary tumor samples, B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone lymphoma showed the strongest activation upon stimulation with CpG oligodeoxynucleotides. Small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and large cell lymphoma showed an intermediate response. Consistent with CpG oligodeoxynucleotides sensitivity, TLR9 mRNA was present in B-CLL but absent in plasmacytoma. Although CpG oligodeoxynucleotides induced proliferation in all CpG oligodeoxynucleotide–sensitive types of B-cell malignancies, proliferation was weaker than in normal B cells and at least for B-CLL was followed by increased apoptosis. In conclusion, B-cell malignancies show significant differences in their responsiveness to CpG oligodeoxynucleotides. Focusing clinical studies on patients with highly CpG oligodeoxynucleotide–sensitive B-cell malignancies may improve the clinical outcome of such trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-1890

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 121

Metadata

Authors
Jahrsdorfer, B., Mühlenhoff, L., Blackwell, S. E., Wagner, M., Poeck, H., Hartmann, E., Jox, R., Giese, T., Emmerich, B., Endres, S., Weiner, G. J., & Hartmann, G.
Venue
Clinical Cancer Research
Published
2005-02-15
Volume
11
Issue
4
Pages
1490-1499
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2124151443
Cited by
121
References
2
FWCI
5.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1890
The paper
Jahrsdorfer, B., Mühlenhoff, L., Blackwell, S. E., Wagner, M., Poeck, H., Hartmann, E., Jox, R., Giese, T., Emmerich, B., Endres, S., Weiner, G. J., & Hartmann, G. (2005). B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.